Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: Data from the tax327 study

Robert J. Van Soest, Ellen S. De Morrée, Liji Shen, Ian F. Tannock, Mario Eisenberger, Ronald De Wit

Research output: Contribution to journalArticle

Abstract

Background Since 2004, docetaxel has been the standard first-line systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). With abiraterone recently becoming available in the predocetaxel setting, it is warranted to identify subgroups of patients who may obtain the greatest benefit from docetaxel and particularly qualify for receiving docetaxel as first-line treatment for mCRPC. Objective We aimed to identify factors that could characterize subgroups of patients who obtain the greatest benefit from the use of docetaxel. Design, setting, and participants TAX327 was multinational, randomized, phase 3 study that was conducted from 2000 to 2002 in 1006 men with mCRPC. Intervention Patients were randomized to receive docetaxel every 3 wk (D3), weekly docetaxel (D1), or mitoxantrone every 3 wk (M3), each with prednisone. Outcome measurements and statistical analysis We investigated whether patients with poorly differentiated tumors (Gleason score ≥7) at diagnosis had greater benefit from D3 compared with M3 than patients with better differentiated tumors (Gleason score ≤6). Using a Cox model, we compared overall survival (OS) between the treatment groups within each subgroup of Gleason score. Results and limitations The TAX 327 data showed that the OS benefit of D3 versus M3 was greater in patients with high-grade tumors (median OS: 18.9 vs 14.5 mo; p = 0.009) than in patients with low-grade tumors (median OS: 21.6 vs 20.7 mo; p = 0.674). Limitations of a retrospective analysis apply. Conclusions The survival benefit obtained with docetaxel is most pronounced in patients with high-Gleason-score tumors (Gleason ≥7). In a time of shifting paradigms in mCRPC, with abiraterone becoming available prior to docetaxel chemotherapy, Gleason score may help in selecting patients who obtain the greatest benefit from docetaxel as first-line treatment for mCRPC. Prospective validation of these findings is warranted.

Original languageEnglish (US)
Pages (from-to)330-336
Number of pages7
JournalEuropean Urology
Volume66
Issue number2
DOIs
StatePublished - 2014

Fingerprint

docetaxel
Neoplasm Grading
Castration
Prostatic Neoplasms
Biopsy
Survival
Neoplasms
Mitoxantrone

Keywords

  • Castration-resistant prostate cancer
  • Gleason score
  • Taxanes

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel : Data from the tax327 study. / Van Soest, Robert J.; De Morrée, Ellen S.; Shen, Liji; Tannock, Ian F.; Eisenberger, Mario; De Wit, Ronald.

In: European Urology, Vol. 66, No. 2, 2014, p. 330-336.

Research output: Contribution to journalArticle

@article{878e400372ab45c899936f134eb19cd1,
title = "Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: Data from the tax327 study",
abstract = "Background Since 2004, docetaxel has been the standard first-line systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). With abiraterone recently becoming available in the predocetaxel setting, it is warranted to identify subgroups of patients who may obtain the greatest benefit from docetaxel and particularly qualify for receiving docetaxel as first-line treatment for mCRPC. Objective We aimed to identify factors that could characterize subgroups of patients who obtain the greatest benefit from the use of docetaxel. Design, setting, and participants TAX327 was multinational, randomized, phase 3 study that was conducted from 2000 to 2002 in 1006 men with mCRPC. Intervention Patients were randomized to receive docetaxel every 3 wk (D3), weekly docetaxel (D1), or mitoxantrone every 3 wk (M3), each with prednisone. Outcome measurements and statistical analysis We investigated whether patients with poorly differentiated tumors (Gleason score ≥7) at diagnosis had greater benefit from D3 compared with M3 than patients with better differentiated tumors (Gleason score ≤6). Using a Cox model, we compared overall survival (OS) between the treatment groups within each subgroup of Gleason score. Results and limitations The TAX 327 data showed that the OS benefit of D3 versus M3 was greater in patients with high-grade tumors (median OS: 18.9 vs 14.5 mo; p = 0.009) than in patients with low-grade tumors (median OS: 21.6 vs 20.7 mo; p = 0.674). Limitations of a retrospective analysis apply. Conclusions The survival benefit obtained with docetaxel is most pronounced in patients with high-Gleason-score tumors (Gleason ≥7). In a time of shifting paradigms in mCRPC, with abiraterone becoming available prior to docetaxel chemotherapy, Gleason score may help in selecting patients who obtain the greatest benefit from docetaxel as first-line treatment for mCRPC. Prospective validation of these findings is warranted.",
keywords = "Castration-resistant prostate cancer, Gleason score, Taxanes",
author = "{Van Soest}, {Robert J.} and {De Morr{\'e}e}, {Ellen S.} and Liji Shen and Tannock, {Ian F.} and Mario Eisenberger and {De Wit}, Ronald",
year = "2014",
doi = "10.1016/j.eururo.2013.08.007",
language = "English (US)",
volume = "66",
pages = "330--336",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel

T2 - Data from the tax327 study

AU - Van Soest, Robert J.

AU - De Morrée, Ellen S.

AU - Shen, Liji

AU - Tannock, Ian F.

AU - Eisenberger, Mario

AU - De Wit, Ronald

PY - 2014

Y1 - 2014

N2 - Background Since 2004, docetaxel has been the standard first-line systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). With abiraterone recently becoming available in the predocetaxel setting, it is warranted to identify subgroups of patients who may obtain the greatest benefit from docetaxel and particularly qualify for receiving docetaxel as first-line treatment for mCRPC. Objective We aimed to identify factors that could characterize subgroups of patients who obtain the greatest benefit from the use of docetaxel. Design, setting, and participants TAX327 was multinational, randomized, phase 3 study that was conducted from 2000 to 2002 in 1006 men with mCRPC. Intervention Patients were randomized to receive docetaxel every 3 wk (D3), weekly docetaxel (D1), or mitoxantrone every 3 wk (M3), each with prednisone. Outcome measurements and statistical analysis We investigated whether patients with poorly differentiated tumors (Gleason score ≥7) at diagnosis had greater benefit from D3 compared with M3 than patients with better differentiated tumors (Gleason score ≤6). Using a Cox model, we compared overall survival (OS) between the treatment groups within each subgroup of Gleason score. Results and limitations The TAX 327 data showed that the OS benefit of D3 versus M3 was greater in patients with high-grade tumors (median OS: 18.9 vs 14.5 mo; p = 0.009) than in patients with low-grade tumors (median OS: 21.6 vs 20.7 mo; p = 0.674). Limitations of a retrospective analysis apply. Conclusions The survival benefit obtained with docetaxel is most pronounced in patients with high-Gleason-score tumors (Gleason ≥7). In a time of shifting paradigms in mCRPC, with abiraterone becoming available prior to docetaxel chemotherapy, Gleason score may help in selecting patients who obtain the greatest benefit from docetaxel as first-line treatment for mCRPC. Prospective validation of these findings is warranted.

AB - Background Since 2004, docetaxel has been the standard first-line systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). With abiraterone recently becoming available in the predocetaxel setting, it is warranted to identify subgroups of patients who may obtain the greatest benefit from docetaxel and particularly qualify for receiving docetaxel as first-line treatment for mCRPC. Objective We aimed to identify factors that could characterize subgroups of patients who obtain the greatest benefit from the use of docetaxel. Design, setting, and participants TAX327 was multinational, randomized, phase 3 study that was conducted from 2000 to 2002 in 1006 men with mCRPC. Intervention Patients were randomized to receive docetaxel every 3 wk (D3), weekly docetaxel (D1), or mitoxantrone every 3 wk (M3), each with prednisone. Outcome measurements and statistical analysis We investigated whether patients with poorly differentiated tumors (Gleason score ≥7) at diagnosis had greater benefit from D3 compared with M3 than patients with better differentiated tumors (Gleason score ≤6). Using a Cox model, we compared overall survival (OS) between the treatment groups within each subgroup of Gleason score. Results and limitations The TAX 327 data showed that the OS benefit of D3 versus M3 was greater in patients with high-grade tumors (median OS: 18.9 vs 14.5 mo; p = 0.009) than in patients with low-grade tumors (median OS: 21.6 vs 20.7 mo; p = 0.674). Limitations of a retrospective analysis apply. Conclusions The survival benefit obtained with docetaxel is most pronounced in patients with high-Gleason-score tumors (Gleason ≥7). In a time of shifting paradigms in mCRPC, with abiraterone becoming available prior to docetaxel chemotherapy, Gleason score may help in selecting patients who obtain the greatest benefit from docetaxel as first-line treatment for mCRPC. Prospective validation of these findings is warranted.

KW - Castration-resistant prostate cancer

KW - Gleason score

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=84904059687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904059687&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2013.08.007

DO - 10.1016/j.eururo.2013.08.007

M3 - Article

C2 - 23957945

AN - SCOPUS:84904059687

VL - 66

SP - 330

EP - 336

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 2

ER -